Sverige - svenska - Läkemedelsverket (Medical Products Agency)

medice arzneimittel pütter gmbh & co. kg - atomoxetinhydroklorid - filmdragerad tablett - 10 mg - atomoxetinhydroklorid 11,43 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

aristo pharma gmbh - atorvastatinkalciumtrihydrat - filmdragerad tablett - 20 mg - atorvastatinkalciumtrihydrat 20,68 mg aktiv substans; laktosmonohydrat hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

aristo pharma gmbh - atorvastatinkalciumtrihydrat - filmdragerad tablett - 40 mg - atorvastatinkalciumtrihydrat 41,36 mg aktiv substans; laktosmonohydrat hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

aristo pharma gmbh - atorvastatinkalciumtrihydrat - filmdragerad tablett - 30 mg - atorvastatinkalciumtrihydrat 31,02 mg aktiv substans; laktosmonohydrat hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

aristo pharma gmbh - atorvastatinkalciumtrihydrat - filmdragerad tablett - 80 mg - atorvastatinkalciumtrihydrat 82,72 mg aktiv substans; laktosmonohydrat hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

aristo pharma gmbh - atorvastatinkalciumtrihydrat - filmdragerad tablett - 10 mg - atorvastatinkalciumtrihydrat 10,34 mg aktiv substans; laktosmonohydrat hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

aristo pharma gmbh - atorvastatinkalciumtrihydrat - filmdragerad tablett - 60 mg - laktosmonohydrat hjälpämne; atorvastatinkalciumtrihydrat 62,04 mg aktiv substans

Europeiska unionen - svenska - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vacciner - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. användning av detta vaccin bör ske i enlighet med officiella rekommendationer.

Europeiska unionen - svenska - EMA (European Medicines Agency)

roche registration gmbh - satralizumab - neuromyelitis optica - immunsuppressiva - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

hameln pharma gmbh - daptomycin - pulver till injektions-/infusionsvätska, lösning - 350 mg - daptomycin 350 mg aktiv substans